Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has confirmed a key patent has been published that could pave the way for treatments in age-related disease prevention.
An application has been to the European Patent Office titled 'Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases' under the reference number EP 4 338 267.
It emanates from Genflow's collaborations with the University of Rochester, The Trustees of Columbia University, and the Albert Einstein College of Medicine,
Genflow CEO Dr Eric Leire said: "This approval from the European Patent Office highlights the innovative spirit of our collaborative team and we are incredibly proud to be part of this pioneering research alongside such respected institutions."
The patent is focused on the SIRT6 protein, which plays a crucial role in DNA repair, metabolism, and longevity, specifically in regulating DNA damage repair and delaying cellular ageing.
Genflow's leading drug candidate, GF-1002, introduces a centenarian variant of the SIRT6 gene, aiming to provide therapeutic benefits, initially targeting non-alcoholic steatohepatitis (NASH) patients. NASH is the most severe form of non-alcoholic fatty liver disease, often asymptomatic and lacking effective treatments.
In 2023, Genflow received positive feedback from the Federal Agency for Medicines and Health Products in Belgium and expects to conduct a follow-up meeting in the second quarter to finalise the design for phase II trials.
CEO Leire said: "This patent represents a leap forward in our understanding and capabilities in treating age-related conditions and marks a significant step forward in our mission to develop effective therapies for NASH and other age-related diseases."